Cleveland BioLabs Stock Forecast, Price & News

-0.13 (-2.44 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume24,401 shs
Average Volume266,804 shs
Market Capitalization$80.44 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter.

Cleveland BioLabs logo

About Cleveland BioLabs

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences. The company was incorporated in 2003 and is headquartered in Buffalo, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.64 out of 5 stars

Medical Sector

1388th out of 2,100 stocks

Pharmaceutical Preparations Industry

622nd out of 832 stocks

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What stocks does MarketBeat like better than Cleveland BioLabs?

Wall Street analysts have given Cleveland BioLabs a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cleveland BioLabs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cleveland BioLabs?

Cleveland BioLabs saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 30,100 shares, an increase of 21.4% from the May 13th total of 24,800 shares. Based on an average daily trading volume, of 122,100 shares, the short-interest ratio is presently 0.2 days. Currently, 0.4% of the shares of the company are short sold.
View Cleveland BioLabs' Short Interest

When is Cleveland BioLabs' next earnings date?

Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Friday, June 18th 2021.
View our earnings forecast for Cleveland BioLabs

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share for the quarter. The biotechnology company earned $0.16 million during the quarter. Cleveland BioLabs had a negative trailing twelve-month return on equity of 42.74% and a negative net margin of 382.26%.
View Cleveland BioLabs' earnings history

How has Cleveland BioLabs' stock been impacted by Coronavirus (COVID-19)?

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CBLI shares have increased by 65.1% and is now trading at $5.20.
View which stocks have been most impacted by COVID-19

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the following people:
  • Mr. Christopher Zosh, VP of Fin., Interim Principal Exec. Officer, Principal Financial Officer & Accounting Officer (Age 45, Pay $121.44k)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 65, Pay $26.05k)
  • Dr. Langdon L. Miller, Chief Medical Officer (Age 67, Pay $23.1k)

Who are some of Cleveland BioLabs' key competitors?

What other stocks do shareholders of Cleveland BioLabs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX).

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

Who are Cleveland BioLabs' major shareholders?

Cleveland BioLabs' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (1.40%), Renaissance Technologies LLC (0.84%), Geode Capital Management LLC (0.29%), ARS Investment Partners LLC (0.24%), Citadel Advisors LLC (0.24%) and Citadel Advisors LLC (0.24%).
View institutional ownership trends for Cleveland BioLabs

Which institutional investors are selling Cleveland BioLabs stock?

CBLI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Cleveland BioLabs
or view top insider-selling stocks.

Which institutional investors are buying Cleveland BioLabs stock?

CBLI stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, ARS Investment Partners LLC, Cambridge Investment Research Advisors Inc., Geode Capital Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Northern Trust Corp.
View insider buying and selling activity for Cleveland BioLabs
or or view top insider-buying stocks.

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $5.20.

How much money does Cleveland BioLabs make?

Cleveland BioLabs has a market capitalization of $80.44 million and generates $260,000.00 in revenue each year.

How many employees does Cleveland BioLabs have?

Cleveland BioLabs employs 2 workers across the globe.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is

Where are Cleveland BioLabs' headquarters?

Cleveland BioLabs is headquartered at 73 HIGH STREET, BUFFALO NY, 14203.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.